ESR1 and breast cancer: TROPION-Breast01 has met accrual, and a press release from AstraZeneca indicates that there are beneficial effects on PFS for ER/PR+/HER-0, 1+ or 2+ and ISH-negative in this trial, favoring Dato-DXd (https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html, accessed on 29 September 2023).